- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00619203
Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis (GLYIP)
Oral Glycerol and High-Dose Rectal Paracetamol to Improve the Prognosis of Childhood Bacterial Meningitis - A Prospective, Randomized, and Double-Blind Clinical Study Using a Two-by-Two Factorial Design
Bacterial meningitis remains a significant cause of morbidity and mortality in children, especially in countries with limited resources. Efforts to improve the grim outcome have included altering the first line antibiotic therapy, controlling seizures and managing fluids more carefully. Adjuvant therapy of steroids has been used with limited success in children in the West and with no proven value in Malawi and other resource constrained settings. Glycerol has been used to reduce brain oedema in neurosurgery and it has recently been shown to reduce morbidity in childhood meningitis in South America. Paracetamol in a high dosage has been shown to reduce inflammation and cytokine levels in septicaemia with improved outcomes in adults.
In Malawi the investigators have tried adjuvant steroids with no improvement in outcome of childhood meningitis. They have recently concluded a study of ceftriaxone which has shown no improvement in mortality though there is less hearing loss than with chloramphenicol and benzyl penicillin.
Following the encouraging results of the Childhood South American Study it is important to assess the use of adjuvant glycerol in children in the investigators' setting. Paracetamol is routinely used in meningitis because of the accompanying fever and headache. This is an opportunity to study its place as adjuvant therapy more carefully than has previously been done.
The investigators propose a prospective, randomized, double blind 2 by 2 factorial designed study to assess the advantage of ceftriaxone (antibiotic) given with paracetamol and glycerol in combination, singly or with neither adjuvant therapy in childhood bacterial meningitis.
Study Overview
Status
Conditions
Detailed Description
Bacterial meningitis (BM) is a major cause of morbidity and death in the developing world. Hib and pneumococcal conjugate vaccines have the potential to prevent meningitis but neither vaccine is available in many countries with limited resources. New (and expensive) antimicrobials have done little to improve the prognosis. A background of HIV infection in many parts of the world adds to the grim prognosis of childhood BM. Adjuvant dexamethasone has gained much attention, because of its effects in damping the host's inflammatory response in childhood BM. However, little or no clinical benefit has been observed in several studies. Most importantly, the first sufficiently powered study in Malawi found no benefit at all. Another sufficiently powered (N=654) study on childhood BM, recently completed in Latin America, showed little benefit of dexamethasone even in Hib meningitis but did show benefit from adjuvant oral glycerol.
It is not known how glycerol works, and there is probably more than one mechanism. One-third of children with bacterial meningitis suffer from significantly reduced cerebral blood flow caused by intracranial oedema. Glycerol slightly increases serum osmolality, and this small change may improve rheology and enhance cerebral circulation, perhaps by increasing perfusion pressure. Thus, extravascularization of water and hidden hypovolemia is improved. Osmotic diuresis is of less importance, because urinary output does not increase with these doses (6 ml/kg/day) of glycerol. A gradient between the body compartments would require an intact or nearly intact blood brain barrier (BBB), and that is not the case in BM. Glycerol is also a scavenger of free oxygen radicals. This activity may alleviate the inflammation characteristic of BM.
Paracetamol is used widely as an antipyretic, analgesic, and anti inflammatory agent. It is effective, safe, inexpensive, and available as a syrup, tablet, suppository and injection; it suits all ages. The effect is dose-dependent. There are very few contraindications, eg allergy. The mechanisms are not well understood, but NSAIDs dampen inflammatory reactions other than those mediated by inhibition of arachidonic acid metabolism. There are differences between paracetamol and other NSAIDs: paracetamol inhibits the centrally located COX 3 and NMDA receptors, other NSAIDs inhibit COX 2 receptors in periphery. These mechanisms may partly explain the different results in patient outcome. In a retrospective analysis of 809 adult patients with bacteremia in Finland, those who received paracetamol had a better survival rate than those treated with other NSAIDs or salicylate.
A prospective clinical trial on childhood BM in which the value of glycerol is reviewed, and the potential of paracetamol is examined is warranted. Both adjuvants aim to improve the poor prognosis of this disease.
Objectives
A Prospective, Randomized, and Double-Blind Clinical Study Using a Two-by-Two Factorial Design to answer two questions:
- Can the prognosis of childhood BM be improved by giving adjuvant oral glycerol?
- Can the outcome be further improved by large doses of rectal paracetamol?
The primary end points are:
- death,
- severe neurological sequelae on discharge
- post meningitis, severe, sensorineural hearing loss on hospital discharge.
Various patient characteristics are taken into account as covariates, eg severity of illness, age, aetiological agent, haemoglobin level, HIV status and presence of malaria co-infection.
The secondary end points are
1. audiological or neurological sequelae (according to the Denver-II developmental screening test).
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Blantyre, Malawi, 3
- College of Medicine, Queen Elizabeth Central Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- All children aged ≥ 2 months, admitted to Queen Elizabeth Hospital, Blantyre, Malawi, with possible or confirmed acute bacterial meningitis
Exclusion Criteria:
- Age less than two months
- Trauma
- Relevant underlying illness such as intracranial shunt, previous neurological disease (cerebral palsy, Down's syndrome)
- Previous permanent hearing loss (not conductive hearing loss) if known
- Immunosuppression except HIV infection.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: D
|
2 placebos, one po, one suppository
|
Active Comparator: A
Two active ingredients
|
glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol 1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses |
Active Comparator: B
One active ingredient
|
paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
|
Active Comparator: C
One (other) active ingredient
|
paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Primary end points are death, severe neurological sequelae, hearing loss.
Time Frame: 2008-2011
|
2008-2011
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Secondary end points are audiological or neurological sequelae (according to the Denver-II developmental screening test).
Time Frame: 2008-2011
|
2008-2011
|
Collaborators and Investigators
Investigators
- Principal Investigator: Elizabeth M Molyneux, FRCPCH, College of Medicine, Blantyre, Malawi
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Central Nervous System Diseases
- Nervous System Diseases
- Infections
- Central Nervous System Infections
- Bacterial Infections
- Bacterial Infections and Mycoses
- Central Nervous System Bacterial Infections
- Meningitis
- Meningitis, Bacterial
- Physiological Effects of Drugs
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Antipyretics
- Protective Agents
- Cryoprotective Agents
- Acetaminophen
- Glycerol
Other Study ID Numbers
- P.03/07/499
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bacterial Meningitis
-
Rambam Health Care CampusWithdrawnGram Negative Meningitis | Post Traumatic Bacterial MeningitisIsrael
-
Prof. Elizabeth MillerNovartis VaccinesCompletedMeningococcal Meningitis, Serogroup A | Meningococcal Meningitis, Serogroup B | Meningococcal Meningitis, Serogroup C | Meningococcal Meningitis, Serogroup Y | Meningococcal Meningitis, Serogroup WUnited Kingdom
-
Beijing Children's HospitalFirst Affiliated Hospital of Xinjiang Medical University; Xingtai People's... and other collaboratorsUnknownNext Generation Sequencing | Pediatric Bacterial MeningitisChina
-
Charite University, Berlin, GermanyRecruitingBacterial Meningitis | Implant Infection | Fungal MeningitisGermany
-
Chiron CorporationUnknownMeningococcal Disease; Meningococcal MeningitisUnited Kingdom
-
Kamuzu University of Health SciencesCompletedInfant Bacterial MeningitisMalawi
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisRussian Federation
-
Sanofi Pasteur, a Sanofi CompanyCompletedMeningitis | Meningococcal Infections | Meningococcal MeningitisUnited States, Puerto Rico
-
Novartis VaccinesCompleted
Clinical Trials on Glycerol and paracetamol
-
Francisco Javier Martínez NogueraCompletedAntioxidative Stress | Lactate Blood Increase | Performance Enhancing Product Use | Change, Body Weight | Change, Body Temperature | Thermal Sensation DisordersSpain
-
University of PittsburghHorizon Pharma Ireland, Ltd., Dublin IrelandCompletedMedium-chain Acyl-CoA Dehydrogenase (MCAD) DeficiencyUnited States
-
Orion Corporation, Orion PharmaCompleted
-
Ultragenyx Pharmaceutical IncCompletedGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)United States, Spain, Australia, France, Israel, Italy, United Kingdom
-
Institut National de la Santé Et de la Recherche...Completed
-
Robert Squires, Jr.No longer available
-
Laboratoires CARILENECompleted
-
University of Texas Southwestern Medical CenterNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); National...TerminatedHepatic Insufficiency | HypoalbuminemiaUnited States
-
University of AarhusRecruitingLow Anterior Resection Syndrome | Rectal CancerDenmark
-
University of BergenUnknown